What is KPV?
KPV is a tripeptide made of three amino acids: lysine, proline and valine (Lys-Pro-Val). It corresponds to the C-terminal fragment (residues 11–13) of alpha-melanocyte-stimulating hormone (alpha-MSH), a neuropeptide produced by the pituitary and some peripheral tissues. In preclinical research KPV retains the anti-inflammatory character of its parent hormone while lacking its effect on pigmentation, which is what made the molecule interesting for laboratory study of inflammation. In cell experiments (in vitro), KPV enters intestinal epithelial and immune cells through the peptide transporter PepT1, which normally handles the uptake of dietary di- and tripeptides. It is important to stress that these are mechanistic observations from models, not evidence of any effect in humans.
Anti-inflammatory mechanisms: NF-κB and cytokines
The central theme of KPV research is modulation of inflammatory signalling. In cell experiments (in vitro), Dalmasso and colleagues showed that nanomolar concentrations of KPV inhibit activation of the NF-κB and MAP kinase pathways in stimulated intestinal epithelial cells. The consequence was reduced expression of pro-inflammatory mediators: in epithelial cells stimulated with IL-1β, IL-8 mRNA declined, and similar anti-inflammatory behaviour appeared in T cells exposed to TNF-α. A more recent keratinocyte study (in vitro) also attributed inhibition of the MAPK/NF-κB axis to reduced IL-1β secretion. All of this consists of mechanistic observations in cell culture; these are not clinical outcomes and do not support conclusions about efficacy in people.
Models of intestinal inflammation (colitis)
Most preclinical data on KPV come from animal models of inflammatory bowel disease. In the study by Dalmasso and colleagues, oral administration of KPV to mice reduced the severity of colitis induced with dextran sodium sulfate (DSS) or trinitrobenzene sulfonic acid (TNBS): less body-weight loss, lower myeloperoxidase activity and reduced pro-inflammatory cytokine expression in colon tissue were observed. Because the PepT1 transporter is upregulated in inflamed intestine, a link was proposed between its activity and peptide uptake. Everything above applies to mouse models (in animals) and does not constitute evidence of activity in humans, nor any therapeutic claim.
Wound-healing and skin models
Part of the literature examines KPV in the context of tissue repair. Xiao and colleagues loaded KPV into hyaluronic-acid-coated nanoparticles: on epithelial monolayers (in vitro), damaged layers treated with these nanoparticles showed a dose-dependent, faster closure of the "wound" (measured by an impedance sensor), while in a mouse colitis model (in animals) they showed better mucosal recovery and less neutrophil infiltration. A separate keratinocyte study (in vitro) examined the response of skin cells to fine dust (PM10) and associated KPV with reduced oxidative stress and inhibition of the MAPK/NF-κB pathway. Again these are cell and animal models; the data do not support claims of wound healing or skin benefits in humans.
In vitro antimicrobial activity
Beyond the anti-inflammatory themes, researchers have also described direct antimicrobial activity. In laboratory experiments (in vitro), Cutuli and colleagues reported that alpha-MSH and its C-terminal fragment KPV inhibited colony formation by the bacterium Staphylococcus aureus and reduced the viability and germ-tube formation of the fungus Candida albicans. They proposed elevated intracellular cAMP in the pathogen as a likely mechanism. These observations are confined to cell and microbiological experiments and describe how the peptide behaves under controlled conditions; they do not demonstrate an antimicrobial effect in humans or animals and cannot be read as a basis for any use.
The evidence is preclinical; regulatory status
Crucial for a correct understanding: almost all available data on KPV come from in vitro experiments and animal models. There are essentially no published human clinical trials confirming any of the themes described, and no established human safety or dosing data exist. KPV is not an approved medicine — it holds no marketing authorisation from the European Medicines Agency (EMA) or the US FDA, and it is not registered as a medicine with Slovenia's agency JAZMP. Any inference about health benefits in humans is therefore scientifically unfounded. The substance is appropriately treated solely as an object of laboratory research.
Research Use Only (RUO) and quality
KPV products offered by peptid.si are intended strictly for Research Use Only and are not intended for human or veterinary use, for consumption, or for any clinical application. This article is educational and is not medical advice. Substance quality is essential to reliable research work: for every batch, peptid.si provides laboratory-verified purity together with a publicly accessible certificate of analysis (COA), available in the COA Vault. This lets a researcher check the identity and purity of a specific batch before use and base their work on verifiable data.
References / Links
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al. (2008). PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology. PubMed
- Cutuli M, Cristiani S, Lipton JM, Catania A (2000). Antimicrobial effects of alpha-MSH peptides. Journal of Leukocyte Biology. PubMed
- Xiao B, Xu Z, Viennois E, et al. (2017). Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular Therapy. PubMed
- Sung J, Ju SY, Park S, Jung WK, et al. (2025). Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway. Tissue & Cell. PubMed
